Applied Therapeutics Inc
NASDAQ:APLT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.84
10.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Applied Therapeutics Inc
Applied Therapeutics Inc
Other
Applied Therapeutics Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Applied Therapeutics Inc
NASDAQ:APLT
|
Other
$1.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
-$100m
|
CAGR 3-Years
45%
|
CAGR 5-Years
22%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$5.7B
|
CAGR 3-Years
-238%
|
CAGR 5-Years
-114%
|
CAGR 10-Years
-4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$127m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$398.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$1.3B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
Applied Therapeutics Inc
Glance View
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
See Also
What is Applied Therapeutics Inc's Other?
Other
1.5m
USD
Based on the financial report for Dec 31, 2023, Applied Therapeutics Inc's Other amounts to 1.5m USD.
What is Applied Therapeutics Inc's Other growth rate?
Other CAGR 3Y
-15%
Over the last year, the Other growth was -50%. The average annual Other growth rates for Applied Therapeutics Inc have been -15% over the past three years .
You don't have any saved screeners yet
